In drug testing of pain management patients, it is important that a valid sample is collected in order to determine compliance with appropriate use of prescribed drugs and to identify the use of other non-prescribed drugs or illicit substances. The ease of urine sample adulteration makes it important to address the method of collection.

In this presentation, Dr. Daly discusses testing for adulterants and recent action by CMS concerning billing for urine validity tests.

About The Author

Prior to his role as Chief Medical Officer at COLA, Dr. John Daly was the Director of Clinical Laboratories for the Duke University Health System from 2005-2009. A longtime resident of Durham, NC, Dr. Daly was quite active in the local medical community, joining the staffs of three area hospitals and serving as a member of various hospital committees. He earned his M. D. at Cornell University Medical College, and performed his internship and residency in pathology at Duke University Medical Center. He also is a veteran of the U. S. Navy.

Related Posts

Send this to a friend